Synthego clears rival’s patents from CRISPR market at Fed Circ

Judges uphold PTAB’s finding that two Agilent patents are invalid | All claims of patents, which cover guide RNAs, found to be anticipated by prior art.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Federal Circuit revives CRISPR feud citing PTAB errors

13 May 2025 Court partially overturns PTAB decision favouring Broad Institute in the long-running gene-editing patent dispute | Case sent back to clarify invention conception | Third parties face "yet more delays" in a patent landscape that appears "constantly in flux".

Europe

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug

22 April 2025 Gene editing company ToolGen “seeks fair licensing agreement” for alleged infringement by rival | High-value sickle cell treatment CASGEVY was “born from ToolGen’s proprietary CRISPR RNP tech” says complaint | Potter Clarkson instructed.

Biotechnology

The new IP battleground in CRISPR-Cas

21 November 2023 Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.

More features

Why AI is changing the patent rules faster than anyone can keep up

Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?

The hidden code in life sciences deals

LSPN panel unpacks critical IP risks in deal-making

A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order

Less is more: patent lawyers flip the script after Amgen

‘Doing more with less’: In-house counsel on budgets and strategy

End of the ‘Death Squad’? Squires puts PTAB on trial

Synthego clears rival’s patents from CRISPR market at Fed Circ

More on this story

Editor's picks

Editor's picks

More features